| scholarly article | Q13442814 |
| P2093 | author name string | N Agrawal | |
| D J Walsh | |||
| M Shou | |||
| K Kassahun | |||
| R A Halpin | |||
| A D Rodrigues | |||
| D E Slaughter | |||
| C Rodeheffer | |||
| I S McIntosh | |||
| L A Geer | |||
| P433 | issue | 6 | |
| P304 | page(s) | 813-820 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor | |
| P478 | volume | 29 |
| Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
| Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
| Q35016968 | Etoricoxib |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q33934086 | Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q46382423 | Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib |
| Q37052864 | Risk management profile of etoricoxib: an example of personalized medicine |
| Q35028375 | The second generation of COX-2 inhibitors: what advantages do the newest offer? |
| Q88338782 | [Update palliative pain therapy] |
Search more.